Pfizer Launches Trial of Omicron-Specific COVID-19 Vaccine
U.S.-based pharmaceutical giant Pfizer and its German partner, BioNTech, announced Tuesday they have begun a clinical trial of a new version of their COVID-19 vaccine specifically designed to protect against the omicron variant of the coronavirus. The companies said in a joint statement that it will test the new vaccine as both a primary and booster dose in more than 1,400 healthy adult volunteers between the ages of 18 and 55. Researchers will separate the volunteers into three groups. The first group... Читать дальше...